Sun Pharma Announces USFDA Approval for Nicardipine Injection

Sun Pharma Announces USFDA Approval for Nicardipine Injection


Mumbai, Maharashtra, India, Wednesday, November 18, 2009 -- (Business Wire India)
 
 Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that the USFDA has granted its subsidiary an approval for its application for Nicardipine Hydrochloride Injections.

These Nicardipine Hydrochloride Injections are available as 25 mg/10ml single use ampuls containing 2.5 mg/ml of the drug, and have annual sales of approximately USD 170 million in the US.

These injections are used for the short-term treatment of hypertension when oral therapy is not feasible or not desirable.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com. 

Suggested Articles

After culling a $2.6 billion biobucks pact last year, Bristol Myers Squibb is making a second and final cut to its pact with I-O biotech Jounce.

With its $400 million Fund XII, Atlas Venture became the latest VC shop to close a major fund since the WHO officially declared COVID-19 a pandemic.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.